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The involvement of Rho GTPases in signal transduction pathways leading to transcription
activation is one of the major roles of this family of GTPases. Thus, the identification of transcrip-
tion factors regulated by Rho GTPases and the understanding of the mechanisms of their
activation and its biological outcome are of great interest. Here, we provide evidence that Rho
GTPases modulate Stat5a, a transcription factor of the family of signal transducers and activators
of transcription. RhoA triggers tyrosine phosphorylation (Y696) of Stat5a via a JAK2-dependent
mechanism and promotes DNA-binding activity of Stat5a. Tyrosine phosphorylation of Stat5a is
also stimulated physiologically by lysophosphatidic acid (LPA) in a Rho-dependent manner.
Simultaneously, RhoA reduces serine phosphorylation of Stat5a at both serine residues S726 and
S780, resulting in a further increase of activity as defined by mutagenesis experiments. Further-
more, serine dephosphorylation of Stat5a by RhoA does not take place by down-modulation of
either JNK1, MEK1, or p38 MAP kinases, as determined by transfection experiments or chemical
inhibition of both MEK1, p38, and JNK serine kinases. Thus, RhoA regulates Stat5a via tyrosine
phosphorylation and via a yet to be determined novel down-modulating pathway that involves
serine dephosphorylation. Finally, we provide evidence for a role of Stat5a in RhoA-induced
epithelial-to-mesenchymal transition with concomitant increase in vimentin expression, E-cad-
herin down-regulation, and cell motility.
INTRODUCTION
Rho GTPases are a multimember family of molecular
switches that belong to the Ras superfamily. Rho GTPases
are involved in regulation of cellular functions such as cell
cytoarchitecture and signal transduction, which relate to cell
growth, development, apoptosis, tumorigenesis, and metas-
tasis (Van Aelst and D’Souza-Schorey, 1997; Aznar and
Lacal, 2001a,b; Bar-Sagi and Hall, 2000; Ridley, 2001). One of
the most critical functions of Rho GTPases is the regulation
of transcription through a variety of transcription factors
(Van Aelst and D’Souza-Schorey, 1997; Aznar and Lacal,
2001a,b). Until recently, little has been known about the
relationship between specific Rho-mediated regulation of
transcription and cellular function. However, transcription
factors modulated by Rho GTPases and the intracellular
pathways that mediate their effects in the context of Rho
GTPases are starting to be identified. Thus, some of the links
between cell adhesion, motility, cell-cycle regulation, devel-
opment, apoptosis, cytoskeletal rearrangements, transfor-
mation, and metastasis, with transcriptional regulation in
the context of Rho, have been described (for review, see
Aznar and Lacal, 2001b).
Rho GTPases activate nuclear factor (NF)-B (Perona et al.,
1997; Montaner et al., 1998, 1999), serum response factor
(SRF) (Hill et al., 1995; Alberts et al., 1998; Montaner et al.,
1999), and transcription factors (TFs) that depend on the
JNK and p38 MAP kinase pathways. Substrates to these
kinases include ELK, PEA3, ATF2, MEF2A (Marinissen et al.,
2001), Max, and CHOP/GADD153 (Van Aelst and D’Souza-
Schorey, 1997). However, the relationship of some of these
TFs with Rho-induced cellular responses is complex. For
instance, discrepancies have been described with respect to
the activation of the SRF and its interdependence on Rho-
mediated cytoskeletal rearrangements (Sahai et al., 1998;
Zohar et al., 1998; Sotiropoulos et al., 1999).
The role of Rho GTPases in cellular transformation has
attracted great attention in the past 5 years. The link between
transcription with transformation, cell invasion, and metas-
tasis is particularly interesting. Ever since it was shown that
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overexpression of either RhoA, Rac1, or Cdc42 transforms
and promotes the metastatic phenotype of cultured 3T3
fibroblasts (Ballestero et al., 1991; Perona et al., 1993; del Peso
et al., 1997), many studies have described the physiological
relevance of Rho signaling and overexpression in human
tumors (Clark et al., 2000; Mira et al., 2000; Van Golen et al.,
2000a,b; Abraham et al., 2001; Kamai et al., 2001; Keely, 2001;
Matsumoto et al., 2001; Takamura et al., 2001; Takemoto et al.,
2001). Overexpression of Rho GTPases occurs in many types
of human tumors, and RhoA and Rac2 constitute early
markers for tumor progression of head and neck squamous
cell cancer (Abraham et al., 2001). Accordingly, a role for
RhoA in uPAR transcription and expression has been de-
scribed (Muller et al., 2000). Activation of oncogenic RhoA
by extracellular matrix signals such as laminin or fibronectin
stimulates transcription of the uPAR gene promoter region
and results in enhanced motility and invasiveness of cells
(Bourdoulous et al., 1998). Which RhoA-modulated tran-
scription factors are involved in this process is unknown,
but the presence of AP-1– and NF-B–responsive elements
in the uPAR promoter points to a role of both TFs in this
process (Dang et al., 1999; Wang et al., 2000). Furthermore,
NF-B has also been related to Rho GTPase–induced neo-
plastic transformation (Whitehead et al., 1999). Recently,
Marinissen et al. (2001) described the role of two other tran-
scription factors, ATF2 and MEF2A, in RhoA-mediated
transformation via transcription of the c-jun gene. Further-
more, Rho GTPases promote the transcription and expres-
sion of cyclin D1, which is directly related to cell cycle entry
and enables aberrant cell growth of tumoral cells (Westwick
et al., 1997; Danen et al., 2000; Welsh et al., 2001). Additional
transcriptional regulatory effects and transcription factors
modulated by Rho GTPases have been described and thor-
oughly reviewed (Van Aelst and D’Souza-Schorey, 1997;
Aznar and Lacal, 2001a,b; Charron et al., 2001; Delarue et al.,
2001).
We have recently reported that oncogenic RhoA and
Cdc42 activate the transcription factor Stat3 in human HEK
cells and other cell lines (Aznar et al., 2001). RhoA induces
both tyrosine and serine phosphorylation of Stat3 by JAK2-
and JNK1-dependent pathways, respectively. Furthermore,
Stat3 is essential for RhoA-mediated neoplastic transfor-
mation, because two dominant negative Stat3 mutants com-
pletely reverted Rho-induced anchorage–independent growth
of human cells (Aznar et al., 2001). Other reports have related
Stat3 with Rac1, and although the serine phosphorylation path-
way appears to be SEK-1–dependent, the mechanism of Rac1-
induced tyrosine phosphorylation is not yet fully understood
(Schuringa et al., 2000; Simon et al., 2000; Faruqi et al., 2001;
Schuringa et al., 2001).
Stat transcription factors constitute a large family of
latent cytoplasmic transcription factors implicated in li-
gand-dependent growth stimulation or differentiation
and in antiproliferative effects (Darnell, 1997). Seven
mammalian Stat genes have been identified thus far. Here,
we have investigated the effect of Rho GTPases on the
regulation of Stat5. Two separately encoded Stat5 tran-
scription factors, Stat5a and Stat5b, coexist (Grimley et al.,
1999). Although Stat5 was initially discovered as a pro-
lactin-stimulated ovine mammary gland factor (Gouilleux
et al., 1994), it has become evident that a large number of
different cytokines, growth factors, and oncogenes pro-
mote tyrosine phosphorylation and transcriptional activa-
tion of Stat5a and Stat5b (Grimley et al., 1999). Activation
of Stat5 follows a paradigm common to all Stat proteins,
in which phosphorylation of a single C-terminal tyrosine
residue promotes Stat oligomerization via their SH2 do-
mains, nuclear migration, and DNA binding to specific
elements. These include primarily cytokines of class I and
class II superfamilies, which couple to receptors that lack
intrinsic tyrosine kinase activity and therefore utilize a
cytoplasmic tyrosine kinase to phosphorylate Stat5a/b.
The main family of cytoplasmic tyrosine kinases that mediate
this process is the Janus kinase (JAK) family (Shuai et al., 1992;
Stahl et al., 1995; Darnell, 1997). In addition, growth factor–
stimulated receptor tyrosine kinases (RTKs) such as the
insulin receptor, epidermal growth factor receptor, and
platelet-derived growth factor receptor promote tyrosine
phosphorylation of Stat5a on ligand binding, which might
be JAK-independent (Davud et al., 1996; Chen et al., 1997;
Valgeirsdottir et al., 1998). As with Stat3, Src family kinases
have been also reported to directly phosphorylate and acti-
vate Stat5 (Yu et al., 1997).
In addition to tyrosine phosphorylation, serine phosphor-
ylation is another frequent mechanism by which Stat activity
is modulated (Wen et al., 1995; Wen and Darnell, 1997;
Decker and Kovarik, 2000). Although serine phosphoryla-
tion of Stat1 and Stat3 positively modulates their transcrip-
tional activity (Wen et al., 1995), the functional and biological
implications of Stat5a/b serine phosphorylation appear to
be more complex. Whereas two different Stat5a serine resi-
dues (S726 and 780) are susceptible to phosphorylation, only
one has been found in Stat5b (S730) (Yamashita et al., 1998,
2002). Also, the impact of Stat5a/b serine phosphorylation
on transcriptional activity might depend greatly on the cell
type used as well as the DNA element chosen (Yamashita et
al., 1998; Park et al., 2001). In this sense, phosphorylation of
both Ser726 and Ser780 of Stat5a and Ser730 of Stat5b neg-
atively regulate Stat5a/b transactivation in prolactin stimu-
lation of the mammary gland (Yamashita et al., 1998).
Subsequent bursts of glucocorticoids inhibit serine phos-
phorylation, eliminating its inhibitory effect, which trans-
lates into increased Stat5a/b activity and milk production
(Beadling et al., 1996). Conversely, growth hormone (GH)
stimulation of a GH-responsive luciferase reporter is posi-
tively dependent on Ser730 of Stat5b and Ser780 but not
Ser726 of Stat5a (Yamashita et al., 2001). Finally, Stat5a/b
transcriptional activity can be also regulated by interaction
with other nuclear proteins (Grimley et al., 1999, Groner et
al., 2000).
Here, we demonstrate that oncogenic RhoA induces
activation of Stat5a by a mechanism that involves both
tyrosine phosphorylation and reduction of serine phos-
phorylation. Also, we identify LPA as a physiological
stimulus that induces tyrosine phosphorylation of Stat5a
via RhoA. With respect to the biological effect of RhoA,
we also show that Stat5a is necessary for the epithelial-
to-mesenchymal transition (EMT) induced by oncogenic
RhoA. Thus, Rho GTPases may modulate Stat5a in a
manner that integrates other cell type– dependent signals
and that differs mechanistically from that involved in Rho
GTPase–induced Stat3 activation.
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MATERIALS AND METHODS
Cell Culture, Transfections, and Chemical Inhibitors
Madin–Darby canine kidney (MDCK) epithelial cells, Chinese ham-
ster ovary 4 cells (CHO4), and human mammary carcinoma cells
(MCF-7) were cultured in DMEM supplemented with 10% fetal
bovine serum and 1 mM glutamine. For transient expression assays,
2 105 cells were transfected in 33-mm dishes by the Lipofectamine
Plus method as described by the manufacturer (Invitrogen, Life
Technologies, San Diego, CA). The amount of plasmidic DNA was
kept constant at 3–5 g per 33-mm plate with the corresponding
empty vector, and 0.5 g of reporter was transfected in all experi-
ments. Stable cell lines were generated by transfection as described
above and selection with appropriate antibiotics. For MDCK-
RhoAQL–expressing cells, eight independent clones were selected
and maintained in 500 g/ml G418 (Sigma, St. Louis, MO). For
Stat5DN and Stat5awt stable cell lines, MDCKs-RhoAQL were
transfected with 2.0 g of Stat5 expression vectors together with 0.2
g of pHygro, and selection was performed with 500 g/ml G418
and 150 g of Hygromycin (Sigma). Four independent clones were
selected for each Stat5a vector. P38 inhibitor SB203580 (Calbiochem,
La Jolla, CA) and MEK1 inhibitor PD98059 (Calbiochem) were used
at a final concentration of 20 and 50 M, respectively. LPA was
purchased from Sigma and was used at a concentration of 50 M at
the indicated times.
Plasmids
PCDNAIIIB plasmid (Invitrogen) and derived expression vectors
encoding for constitutively activated RhoA (QL), Rac1 (QL), and
Cdc42Hs (QL) proteins have been described (Aznar et al., 2001). The
1 Sp1GLECAT contains the Stat5-responsive sequence of the hu-
man Sp2.1 promoter inserted into a pBLCAT5-derived plasmid.
Expression vector for dominant negative JAK2 (pRk-JAK2-KE) and
wild-type JAK2 were kind gifts from Dr. I. M. Kerr. Stat5a, Stat5b,
Stat5a S726A, Stat5a S780A, and Stat5a S726/780A were generated
as described (Yamashita et al., 1998,2001).
Gene Expression Analysis
MDCK, MCF-7, or CHO cells (n  2  105) were transfected with
the indicated plasmids. At 24–36 h after transfection, protein ex-
tracts were prepared by lysis with the commercially available Re-
porter lysis buffer (Promega, Madison, WI). The total amount of
protein was determined with a commercial kit based on the Brad-
ford method (Bio-Rad, Hercules, CA). Protein (2–4 g) was assayed
for chloramphenicol acetyl transferase (CAT) activity by use of a
xylene-based method as described (Aznar et al., 2001). Total counts
(cpm) were detected with a 1214 RackBeta Liquid scintillation
counter (WALLAC, Turku, Finland) and normalized by micrograms
of protein. Transfection efficiencies were corrected by detection of
the expressed proteins by Western immunoblotting.
Western Blot Assays and Antibodies
For protein expression assays, cells were transfected with the cor-
responding plasmids and incubated in DMEM 0.5 or 10% FBS
where indicated for the next 24–36 h. The lysis was performed in
Reporter lysis buffer (Promega) containing 200 M orthovanadate,
50 mM NaF, 20 g/ml leupeptin, 20 g/ml aprotinin, and 1 mM
phenylmethylsulfonyl fluoride. Thirty micrograms of total protein
was analyzed by SDS electrophoresis on 10% polyacrylamide gels
(Bio-Rad). After transfer of proteins to Immobilon-P PVDF mem-
brane (Millipore, Bedford, MA), the blots were incubated with the
corresponding antibodies. Immunocomplexes were visualized by
enhanced chemiluminescence detection (Amersham Biosciences,
Arlington Heights, IL) with either an anti-rabbit or anti-mouse
antibody conjugated to peroxidase (Santa Cruz Biotechnology,
Santa Cruz, CA). -Stat5 monoclonal antibody was purchased from
Transduction Laboratories (Lexington, KY), phospho-Stat5a/b (Tyr
694/699) and phospho-Stat5a/b (Ser 726/731) were purchased from
Upstate Biotechnology (Lake Placid, NY), and all were used as
indicated by the manufacturer. Rabbit antiserum against Stat5a-
Ser780 was generated as described (Yamashita et al., 2001). For gel
supershift analysis, anti-Stat5a was purchased from Santa Cruz
Biotechnology. Mouse monoclonal anti-phospho-p44/42 MAP ki-
nase (Thr202/Tyr204) and anti-phospho p38 were purchased from
New England Biolabs (Beverly, MA). JAK2-, RhoA-, and vimentin-
specific polyclonal antibodies were obtained from Santa Cruz Bio-
technology.
Electrophoretic Mobility Shift Assays
For electrophoretic mobility shift assay (EMSA) assays, cells were
transfected with the corresponding plasmids and incubated in
DMEM–0.5% FBS for 36 h. Nuclear extracts were obtained as de-
scribed (Perona et al., 1997). Nuclear protein was measured with a
commercial kit based on the Bradford method (Bio-Rad). Two mi-
crograms of nuclear protein was then incubated with 0.1 ng of
hProGLE probe (5000 cpm) or with unlabeled probe and subjected
to electrophoresis on a nondenaturing 4% acrylamide:bisacrylamide
gel (29:1) (Bio-Rad). For gel supershift analysis, the nuclear extract
was incubated for 10 min (at room temperature) with anti-Stat5a
(Santa Cruz) before addition of the labeled probe. For nonspecific
competition, an NF-B binding element consisting of a single B site
was used.
Wound-Healing Assay
The indicated cell lines were seeded in 60-mm dishes and main-
tained in normal growth conditions to confluence. At this point, a
wound was inflicted with a sterile tip, and cells were washed twice
with complete DMEM. Cell motility was monitored at 1-hr inter-
vals.
RESULTS
Oncogenic RhoA Induces Tyrosine Phosphorylation
of Stat5a (Y696) but Not Stat5b (Y699) and Stat5a
Transcriptional Activation in MDCK Epithelial
Cells
A phosphospecific antibody that recognizes the tyrosine
phosphorylated form of Stat5a was used to verify whether
oncogenic RhoA (QL) is capable of inducing tyrosine phos-
phorylation of this transcription factor. MDCK cells were
transfected with 2 g of Stat5a expression vector either with
pcDNAIIIB or its derived vector encoding for a constitu-
tively active mutant of RhoA. Cells were maintained in low
serum content (0.5% FBS); 48 h after transfection they were
lysed, and whole-cell extracts were assayed for Stat5a ty-
rosine phosphorylation by Western immunoblotting (Figure
1A, right). RhoA (QL) induces a readily detectable increase
in Stat5a tyrosine phosphorylation. To verify whether these
differences observed were not caused by differential trans-
fection of either Stat5a or RhoA (QL), the same blot was
tested for both Stat5a and RhoAQL expression. As seen in
Figure 1A, the same levels of Stat5a were present in both
lanes, indicating that this effect is specific to RhoA signaling.
Furthermore, equal loading was verified by use of a tubulin-
specific antibody.
The same type of experiment was performed to verify
whether RhoA stimulated tyrosine phosphorylation of
Stat5b. As seen in Figure 1A, left, an antibody that recog-
nizes Stat5b only when phosphorylated on tyrosine 699 did
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not detect any significant tyrosine phosphorylation of Stat5b
in RhoAQL-expressing cells compared with parental MDCK
cells. The observed effect on Stat5a was not a result of
overexpression of the transcription factor along with RhoA,
because a fivefold increase (determined by the relative in-
tensities of the bands) in tyrosine phosphorylation of endog-
enous Stat5a in MDCK cells could be also observed (Figure
1B). Thus, RhoAQL induces tyrosine phosphorylation of
Stat5a but not Stat5b.
Tyrosine phosphorylation of Stat proteins enables their
homodimerization or heterodimerization via their SH2 do-
mains. Protein oligomerization, in turn, triggers a nuclear
localization signal that carries the transcription factor to the
nucleus, where it can interact with Stat-responsive DNA
elements (Darnell, 1997). Thus, we next verified whether
tyrosine phosphorylation of Stat5a by RhoA (QL) leads to an
increase in Stat5a transcriptional activity in MDCK cells and
other epithelial cell lines. A Stat5-responsive element from
the Sp2.1 promoter was cloned upstream of a luciferase
reporter gene, Sp1GLECAT, and Stat5 transcriptional activ-
ity was measured in RhoA (QL) transfectants. PcDNAIIIB
control vector or RhoAQL, Rac1QL, and Cdc42QL were each
cotransfected in MDCK cells with Stat5a expression vector,
along with the Sp1GLECAT reporter, and CAT activity was
measured 48 h after transfection (Figure 2A). Whereas RhoA
induced a twofold to threefold increase in Stat5a transcrip-
tional activity, both Rac1QL and Cdc42QL failed to promote
Stat5a-dependent transcription. Furthermore, the same ef-
fect is observed with two different stable clones that express
RhoA (QL), SP7.29 and SP7.3 (Figure 2B). According to the
functional assay, we verified that Rac1 and Cdc42 do not
induce tyrosine phosphorylation of Stat5a under the same
Figure 1. Oncogenic RhoA induces tyrosine phosphorylation
(Y694) of Stat5a but not Stat5b. (A) MDCK cells transfected with
either 2.0 g of pcDNAIIIB or RhoA (QL), together with 2.0 g of
Stat5a, and harvested 48 h after transfection. Incubation of whole-
cell extracts with a phosphospecific Stat5a-Y696 antibody revealed
that RhoA induces tyrosine phosphorylation of Stat5a (right). Equal
Stat5a transfection was verified with anti-Stat5a antibody. Expres-
sion of RhoA was detected with anti-RhoA antibody, and equal
loading was verified by determining the levels of tubulin. The same
type of experiment was performed with respect to Stat5b, and no
tyrosine phosphorylation of residue 699 was observed under RhoA
signaling (left). (B) RhoAQL induces tyrosine phosphorylation of
endogenous Stat5a. RhoAQL or control vector was transfected in
MDCK cells as in A, and tyrosine phosphorylation of Stat5a was
determined by Western analysis. A and B show representative blots
obtained in three independent experiments with similar results.
Figure 2. Rho GTPases differentially induce Stat5-dependent tran-
scription of the Sp1GLECAT reporter in different cell lines. (A)
RhoA but not Rac1 or Cdc42 (QL) activates Stat5a-dependent tran-
scription of the Sp1GLECAT reporter via the endogenous and ec-
topically expressed Stat5a in MDCK cells. Cells transfected with
Stat5a (2.0 g) or not transfected, together with control vector or
RhoA (QL), along with 0.5 g of Sp1GLECAT reporter, were as-
sayed for CAT activity 48 h after transfection. (B) RhoA (QL) acti-
vates Stat5a transactivation in two stable clones that constitutively
express oncogenic RhoA (QL). MDCK or either clone was trans-
fected with 0.5 g of Sp1GLECAT reporter and 2.0 g of Stat5a, and
CAT activity was measured 48 h after transfection. The levels of
expression of RhoA (QL) were determined with an anti-RhoA poly-
clonal antibody. Equal loading was verified with anti-tubulin anti-
body. (C) RhoA, Cdc42, and Rac1 differentially activate Stat5-de-
pendent transcription in MCF-7 and CHO cells. Transfection of 1.0
g of RhoA, Rac1, or Cdc42 (QL) along with the Sp1GLECAT
reporter was performed in MCF-7 or CHO cells, and CAT activity
was measured 24 h after transfection. (D) RhoC (QL) promotes
Stat5-dependent transcription in HeLa and MCF-7 cells. Same ex-
periment as in C was performed in both cell lines, and CAT activity
was measured 24 h after transfection. All CAT experiments shown
in this figure represent the mean of a single experiment performed
in triplicate SD and are representative of at least three indepen-
dent experiments with similar results.
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conditions as with RhoA (our unpublished observations). A
Western blot against RhoA is shown, and equal loading was
verified with an anti-tubulin antibody. Interestingly, when
other cell lines are verified for Stat5 activity in RhoA (QL),
Rac1 (QL), or Cdc42 (QL) transfectants, a differential pattern
of activation is observed. Thus, in MCF-7 cells, both RhoA
and Cdc42 promote Stat5-dependent transcription, whereas
Rac1 fails to do so (Figure 2C). Conversely, Cdc42 (QL) failed
to activate Stat5 in CHO cells, but both RhoA (QL) and Rac1
(QL) do so (Figure 2C). Furthermore, RhoC promoted Stat5-
dependent transcriptional activation in HeLa and MCF7 cells
(Figure 2D). Thus, Stat5a activation by different members of the
family of Rho GTPases appears to be cell type–specific.
Finally, we verified whether a physiological activator of
RhoA would induce tyrosine phosphorylation of Stat5a. To
this end, we stimulated serum-starved MDCK cells with
LPA for 5, 15, 30, and 60 min and verified tyrosine phos-
phorylation of Stat5a. In addition, dominant negative RhoA
(N19) was expressed transiently in MDCK cells, which were
then stimulated as mentioned with LPA. As observed in
Figure 3A, exposure of MDCK cells to LPA for 5 min in-
duced an approximately fourfold increase in the level of
tyrosine phosphorylated Stat5a (as determined by relative
band intensities) in a RhoA-dependent manner, because
dominant negative RhoA (N19) completely abrogated this
effect. LPA-induced tyrosine phosphorylation of Stat5 was
observed as early as 5 min after stimulation and was sus-
tained up to 30 min (data not shown). Steady-state levels of
Stat5a and efficient expression of RhoAN19 were verified
(Figure 3A). Furthermore, we verified whether LPA-induced
tyrosine phosphorylation of Stat5a would translate into an
increase in the transcriptional activity of the transcription
factor. MDCK cells transfected with control vector or with
dominant negative RhoAN19 along with the Sp1GLECAT
reporter were left under low-serum conditions for 48 h and
subsequently stimulated with LPA for 12 h. LPA-induced
transcriptional activation of Stat5a was found to be weak but
fully dependent on RhoA (Figure 3B). Thus, LPA activates
Stat5 via a signaling pathway that depends on RhoA.
Rho Promotes Binding of Stat5a to the Stat5-responsive
Element of the Human Prolactin Promoter
Tyrosine phosphorylation of Stat proteins promotes their ho-
mo-oligomerization or hetero-oligomerization and subsequent
nuclear migration. Once in the nucleus, Stat5 oligomers may
interact with other accessory nuclear factors and bind to their
consensus sequences to modulate transcription (Grimley et al.,
1999). Because RhoA triggers tyrosine phosphorylation of
Stat5a, we next verified its DNA-binding potential under RhoA
signaling. MDCK cells transfected with either empty vector or
RhoA (QL) together with Stat5a were maintained in low serum
for 36 h. Nuclear-enriched extracts were obtained, and equal
amounts of protein were used to assess Stat5a DNA binding to
the human prolactin gene promoter (hProGLE). Equal
amounts of nuclear extracts from control and Rho-transfected
cells were subjected to EMSA using radiolabeled hProGLE as a
probe (Figure 4). RhoA (QL) transfectants showed a much
more intense binding than control cells (lane 2 vs. lane 1).
Moreover, whereas an NF-B–binding element did not affect
RhoA-dependent Stat5 DNA binding (lane 3), specific compe-
tition with excess amounts of unlabeled probe completely elim-
inated the signal (lane 4). In addition, incubation of nuclear ex-
tracts with anti-Stat5a antibody diminished the intensity of the
two lower bands and eliminated the upper bands (lane 5),
whereas Stat5b, Stat1, c-Jun, or ATF2 antibodies had no effect over
nuclear complex migration (our unpublished observations). Thus,
RhoA induces tyrosine phosphorylation of Stat5a, which pro-
motes its translocation to the nucleus, in which it can interact with
DNA elements responsive to this transcription factor.
RhoA (QL)-induced Tyrosine Phosphorylation of
Stat5a Is Mediated by JAK2 Tyrosine Kinase
Tyrosine phosphorylation of Stat5 is induced by diverse
cytokines and is performed by different tyrosine kinases
(Grimley et al., 1999). We have recently found that RhoA
induces tyrosine phosphorylation of Stat3 in human HEK
Figure 3. LPA induces tyrosine phosphorylation and transcriptional
activation of Stat5a via RhoA. (A) RhoA mediates LPA-induced Stat5a
tyrosine phosphorylation. MDCK cells transfected with 2.0g of Stat5a
and RhoAN19 expression vectors (where indicated) were treated with
50 M LPA for 5 min, and tyrosine phosphorylation of Stat5a was
determined by Western blot analysis. (B) LPA-induced Stat5a tran-
scriptional activation is mediated by RhoA: 2.0 g of control pcD-
NAIIIB or RhoAN19 (where indicated) expression vectors, along with
the Sp1GLECAT reporter, were transfected in MDCK cells. Forty-eight
hours after transfection, cells were treated with 50 M LPA for 12 h,
and CAT activity was determined. CAT experiment shown in this
figure represents the mean of a single experiment performed in tripli-
cate SD and is representative of at least three independent experi-
ments with similar results. A shows a representative result obtained in
three independent experiments.
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cells via a JAK2-dependent pathway. Hence, we have stud-
ied the role of this tyrosine kinase in Stat5a tyrosine phos-
phorylation by oncogenic RhoA. Coexpression of a domi-
nant negative mutant JAK2 (KE mutation) with RhoA, along
with the Sp1GLECAT reporter, resulted in complete inhibi-
tion of RhoA-stimulated Stat5a transcriptional activity, with
little effect over basal Stat5a transcriptional activity (Figure
5A). In addition, whereas expression of wild-type JAK2
produces no significant increase in Stat5a transactivation,
cotransfection with RhoA (QL) leads to a synergism in
Stat5a activity (Figure 5B).
We also needed to verify whether the differences observed in
Stat5a activity were caused by a modulatory effect of JAK2 on
tyrosine phosphorylation of Stat5a in the context of RhoA (QL).
The same extracts as used for CAT activity were tested for Stat5
tyrosine phosphorylation. As shown in Figure 5C, whereas mod-
ulation of JAK2 activity does not have any effect over Stat5 ty-
rosine phosphorylation in MDCK parental cells (left), it does have
a profound effect over Stat5a tyrosine phosphorylation down-
stream of RhoA (QL). Thus, expression of a dominant negative
mutant (JAK2KE) completely eliminated such phosphorylation,
whereas wild-type JAK2 enhanced RhoA-induced tyrosine phos-
phorylation of Stat5a (Figure 5C, right). As a control, expression of
both wild-type and dominant negative JAK2 was verified by use
of an anti-JAK2 specific antibody. Also, expression of RhoA (QL)
was verified and confirmed to be similar in all lanes. Accordingly,
the same result was obtained when the SP7.29 MDCK clone that
constitutively expresses oncogenic RhoA was transfected with
either wild-type or dominant negative JAK2 (Figure 5D). Thus,
JAK2 lies downstream of oncogenic RhoA and mediates tyrosine
phosphorylation of Stat5a, thus enabling its dimerization, DNA
binding, and transcriptional activation.
Figure 4. RhoA (QL) induces Stat5a DNA binding to the GAS
sequence of the human prolactin promoter. Two micrograms of
MDCK-Stat5a or MDCK-RhoAQL/Stat5a nuclear extracts was sub-
jected to EMSA. Lanes 1 and 2 represent control cells and RhoAQL-
transfected cells, respectively. Lanes 3 and 4 correspond to unspe-
cific competition and specific competition with excess hProGLE
probe, respectively. Lane 5 corresponds to competition with
-Stat5a antibody. Results shown are representative of four inde-
pendent experiments.
Figure 5. JAK2 mediates RhoA-induced Stat5a tyrosine phosphor-
ylation. (A) Dominant negative JAK2 inhibits Stat5a transcriptional
activation by RhoA (QL). One microgram of control pcDNAIIIB or
RhoAQL was cotransfected with 1 g of Stat5a, with either 3 g of
pRK-JAK2-KE or pRK control vector, along with 0.25 g of
Sp1GLECAT reporter. CAT activity was measured 48 h after trans-
fection (0.5% FBS). (B) Wild-type JAK2 synergizes with RhoA (QL)
to promote Stat5a-dependent transcription. Same amounts of con-
trol, RhoAQL, and Sp1GLECAT vectors were transfected as in A.
Three micrograms of wild-type JAK2 was transfected where indi-
cated. Data shown in A and B represent a single experiment per-
formed in triplicate SD and are representative of three indepen-
dent experiments. (C) JAK2 acts downstream of RhoA to promote
Stat5a tyrosine phosphorylation, with no effect on basal tyrosine
phosphorylation of Stat5a in control (C) cells. Thirty micrograms of
the same extracts as in A and B were used for Western immuno-
blotting. Levels of JAK2 (KE and wt) and RhoA (QL) were verified
with specific antibodies. (D) Same effect as in C is observed using a
stable RhoA (QL) expressing MDCK cell line (clone SP7.29). Three
micrograms of pRK-JAK2-KE or JAK2wt was transfected, and 48 h
after transfection, protein expression was verified by Western blot.
JAK2 (KE; wt) and Stat5a PY-694 were detected with specific anti-
bodies. Immunoblot shown is representative of two independent
experiments.
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RhoA Inhibits Stat5a Serine Phosphorylation of
Ser726 and Ser780, Preventing Its Inhibitory Effect
on Stat5a Transcriptional Activity
A second regulatory mechanism independent of tyrosine
phosphorylation has been described for several Stat proteins
that involves serine phosphorylation. However, only re-
cently has the effect of Stat5a/b serine phosphorylation on
Stat5 activity begun to be unraveled. Two different serine
residues are phosphorylated on prolactin or GH stimulation
of Stat5a (serines 726 and 780), and only a single serine is
phosphorylated in Stat5b (serine 730). Furthermore, serine
phosphorylation of Stat5a/b appears to constitute a fine-
tuning mechanism of Stat5 activity (Gouilleux et al., 1994;
Yamashita et al., 1998, 2001; Park et al., 2001).
We therefore analyzed the pattern of serine phosphoryla-
tion downstream of oncogenic RhoA (QL). To this end, we
used two phosphospecific antibodies that recognize either
the serine-phosphorylated form of Stat5a on Ser726 or serine
phosphorylated Stat5a on Ser780. In addition, three Stat5a
serine mutants were used that contain a Ser726 or Ser780
mutated to alanine (Stat5a S726A and Stat5a S780A, respec-
tively) and the double mutant (Stat5a S726/780A). Wild-
type Stat5 or the serine mutants S726A and S780A were
cotransfected into MDCK cells with either control vector or
RhoA (QL), and whole-cell extracts were subjected to
Western immunoblotting. Figure 6A shows that RhoA
(QL) reduced the level of Stat5a serine phosphorylation of
both Ser726 and Ser780. To confirm that this effect was not
caused by differential expression of Stat5, the levels of
total Stat5a were verified by use of an anti-Stat5 specific
antibody. Furthermore, RhoA levels were detected to be
equal in extracts derived from RhoA transfectants. Fi-
nally, equal loading was verified by determining the lev-
els of intracellular tubulin. Thus, RhoA (QL) produces an
inhibitory effect over Stat5a serine phosphorylation of
both Ser726 and Ser780.
Next, the functional relevance of the inhibitory effect of
RhoA over serine phosphorylation of Stat5a was investi-
gated. Wild-type Stat5a or either single serine mutant
(S726A, S780A) and the double serine mutant (S726/780)
were coexpressed with RhoA or control vector, along with
the Sp1GLECAT reporter, and CAT activity was measured
(Figure 6B). Surprisingly, abrogation of either serine led to a
twofold to threefold increase in Stat5a transcriptional activ-
ity compared with wild-type activity. Accordingly, Stat5A
S726/780A that completely lacks serine phosphorylation
showed a synergistic increase in activity with respect to
wild-type Stat5a. With the same extracts, the level of serine
Figure 6. RhoAQL reduces the level of Stat5a
serine phosphorylation of serine residues 726 and
780, which leads to an increase in Stat5a activity. (A)
RhoA inhibits Stat5a serine phosphorylation of
serines 726 and 780. Cells were transfected with 2.0
g of control vector, RhoA (QL), and wild-type
Stat5a or serine mutants S726A and S780A as indi-
cated. Forty-eight hours after transfection, cells were
harvested and lysed. Western immunoblotting was
performed with phospho-Stat5a S726 and phospho-
Stat5a S780 antibodies where indicated. Equal ex-
pression of Stat5a RhoAQL was verified with anti-
Stat5a and anti-RhoA antibodies, respectively. Equal
loading was confirmed with anti-tubulin. The blots
shown are representative of five independent exper-
iments. (B) Stat5a serine phosphorylation of both
serines 726 and 780 is inhibitory for Stat5a-depen-
dent Sp1GLE transcription. Control vector or
RhoAQL was cotransfected with the indicated Stat5a
expression vectors, along with the Sp1GLECAT pro-
moter, and CAT activity was measured. (C) Same
extracts were used for Western immunoblotting, and
the levels of Stat5a serine phosphorylation on serine
726 were confirmed to be lower in RhoA transfec-
tants. Levels of Stat5a and RhoA were confirmed to
be equal by anti-Stat5a and anti-RhoA antibodies.
Experiments shown in B and C are representative of
three independent results.
S. Aznar Benitah et al.
Molecular Biology of the Cell46
phosphorylation was detected by Western blot (Figure 6C).
As seen in Figure 6C, a significant reduction in Ser726 phos-
phorylation (approximately 50% reduction in intensity) of
both wild-type Stat5a and Stat5a S780 was observed in
RhoA-expressing cells with respect to control cells. We then
verified the expression of both Stat5a and S780A with an
anti-Stat5 antibody to confirm that these differences in both
transcriptional activity and serine phosphorylation were not
because of their differential expression. As expected, the
levels of both wild-type and serine mutants in control cells
versus RhoA-expressing cells were similar. Furthermore,
this analysis established that the apparent lower levels of
Ser726 phosphorylation of Stat5a S780A mutant with respect
to wild-type Stat5a were a result of lower expression of the
serine mutant. Also, RhoA (QL) was expressed equally in all
RhoA transfectants. Similar results were obtained when the
levels of phosphorylation of serine 780 were studied, al-
though the effect of RhoA on dephosphorylation of this
residue is milder than that obtained with serine 726, with a
reduction of 30% in the content of phosphorylation (our
unpublished observations ).
RhoA-induced Serine Dephosphorylation of Stat5a
Is Not Mediated by MEK-1, p38, or JNK Kinases
Because inhibition of Stat5a serine phosphorylation of both
Ser726 and Ser780 by RhoA translates into an increase in
Stat5a transcriptional activity, we next wanted to determine
which serine kinase is down-modulated by RhoA under
these circumstances that results in this effect. Constitutive
serine phosphorylation of Stat5a in Nb2 lymphoma cells has
been described to be MEK1-dependent, by use of the MEK1
inhibitor PD98059 (Kirken et al., 1997). Thus, we studied the
effect of blocking MEK1 function on RhoA-induced Stat5a
activation. Wild-type Stat5a, Stat5a S726A, or Stat5a S780A
was cotransfected with control vector or RhoA (QL), to-
gether with the Sp1GLECAT reporter. Eight hours after
transfection, cells were treated with PD98059 (50 M) for
16 h, and cells were harvested for CAT assay and Western
immunoblotting. Inhibition of MEK1 in both control cells
and RhoA (QL)–expressing cells resulted in a twofold in-
crease in Stat5a transcriptional activity (Figure 7A). We were
able to determine Ser726 as the PD98059-sensitive Stat5a
Figure 7. MEK1 and RhoA (QL) modulate Stat5a
serine phosphorylation of serine 726 by two inde-
pendent mechanisms. (A) Treatment with MEK1 in-
hibitor PD98059 results in an increase of transcrip-
tional activity of Stat5a and S780A mutant but not
S726 mutant. MDCK cells transfected with 2.0 g of
the expression vectors indicated, together with 0.5
g of Sp1GLECAT reporter, were maintained in 10%
FBS for 24 h after transfection, and CAT activity was
measured. (B) MEK-1 phosphorylates Stat5a serine
726 by a mechanism independent of RhoA. Same
extracts as in A were used to verify the level of Stat5a
serine phosphorylation on MEK-1 inhibition. As a
control of inhibition, the amount of phospho-
ERK1/2 was shown to decrease significantly on
PD98059 treatment. The levels of transfected Stat5a
or serine mutants were verified with specific anti-
Stat5a antibody. (C) Treatment with PD98059 does
not affect phosphorylation of serine 780. Same ex-
tracts as in A and B were used to determine the
levels of Stat5a serine phosphorylation on serine 780.
(D) PD98059 does not affect Stat5a tyrosine phos-
phorylation. Same extracts as in A were used to
perform this experiment. Results shown here are
representative of three independent experiments.
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serine residue, because the S726A mutant was unaffected by
PD98059, whereas the S780A mutant showed an increase in
activity when treated with PD98059 (Figure 7A).
When Stat5a serine phosphorylation was determined by
Western immunoblotting with the same extracts, this obser-
vation was confirmed (Figure 7, B and C). Whereas phos-
phorylation of serine 726 is sensitive to PD98059 treatment,
with an approximate reduction in phosphorylation intensity
of 40% (Figure 7B), phosphorylation of serine 780 remained
unaffected (Figure 7C). The same effect over phosphoryla-
tion of serine 726 was observed with shorter exposures to
PD98059, 6 and 8 h (our unpublished observations). Phos-
pho-ERK1/2 levels were verified as a control of PD98059
functional inhibition. In addition, to study whether RhoA
(QL) directly modulates the activation of MEK1, we verified
the pattern of MEK1 phosphorylation in control cells ver-
sus RhoA transfectants (Figure 7B). The levels of MEK1
phosphorylation were the same in control and RhoA-
transfected cells, indicating that the effects of both MEK1
and RhoA (QL) on Stat5a serine phosphorylation are in-
dependent events and constitute two parallel mechanisms
of Stat5a transcriptional modulation. Finally, we verified
that the differences in transcriptional activity observed
after PD98059 treatment were not a result of changes in
tyrosine phosphorylation of Stat5a, as shown in Figure
7D. Together, treatment with PD98059 and activation of
RhoA (QL) led to an increase in Stat5a transcriptional
activity, presumably as a consequence of the inhibition of
phosphorylation of Ser726.
We also examined the possible effect of p38 and JNK on
RhoA regulation of Stat5a activity using a type of analysis
similar to that for MEK1. Thus, MDCK cells transfected with
either Stat5a, Stat5a S726A, or Stat5a S780A, with control
vector or RhoA (QL), along with the Sp1GLECAT reporter
were treated with the p38-specific inhibitor SB203580. Treat-
ment with SB203580 led to a 2.5-fold increase in Stat5a
activity in RhoA transfectants (our unpublished observa-
tions). However, when either mutant was treated with the
inhibitor, no change in activity was observed with respect to
untreated cells. In addition, analysis of the phosphorylation
of both Ser726 and Ser780 revealed that residues of both
serines remain unaffected by treatment with SB203580. Thus,
p38 negatively regulates Stat5a transcriptional activity by an
unknown mechanism that does not involve direct modula-
tion of serine phosphorylation of the transcription factor,
which is independent of RhoA.
Finally, we verified whether the JNK pathway is involved
in serine dephosphorylation of Stat5a induced by RhoA. To
that end, we expressed in MDCK-RhoAQL–expressing cells
the JNK-binding domain of the scaffold protein JIP1 (called
JIP1) and measured the transcriptional activity of Stat5a
via the Sp1GLECAT reporter (our unpublished observa-
tions). We did not observe any effect on the transcription or
serine phosphorylation of Stat5awt or the serine mutants
S726A and S780A. Therefore, we concluded that the JNK1
pathway is not involved in RhoA-mediated activation of
Stat5a.
Thus, RhoA (QL) down-modulates the activity of a yet to
be identified Stat5a serine kinase, which in turn leads to
activation of Stat5a transcription factor
Stat5a Is Necessary for RhoA-induced EMT in
MDCK Cells
We wanted to study the effect(s) Stat5a could have on RhoA
biological functions. To that end, we generated stable cell
lines of MDCK-RhoAQL cells with Stat5awt or Stat5DN
(Figure 8A). Interestingly, RhoAQL-expressing cells had un-
dergone a readily visible EMT with respect to MDCK cells.
However, whereas the morphology of Stat5DN stable cell
lines resembled that of parental MDCK cells, stable expres-
sion of Stat5awt further potentiated a transition to a fibro-
blastic morphology (representative pictures are shown in
Figure 8B). This effect was confirmed by analysis of the
levels of expression of vimentin. In this sense, expression of
dominant negative Stat5 significantly reduced the levels of
vimentin with respect to MDCK-RhoAQL cells, whereas
Stat5awt potentiated vimentin expression (Figure 8A). Fur-
thermore, these effects were specific to RhoA signaling, be-
cause stable expression of dominant negative Stat5a or
Stat5awt did not significantly change the morphology of the
cells or vimentin expression of the parental MDCK cell line
(Figure 8C).
We next verified the effect Stat5 had over E-cadherin, an
adhesion protein required for adherens junctions whose ex-
pression is lost after EMT. As observed in Figure 8C,
Figure 8.
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whereas Stat5aDN or Stat5awt alone had no effect over
E-cadherin, stable expression of RhoAQL led to complete
down-regulation of E-cadherin. However, coexpression of
dominant negative Stat5a with RhoAQL reverted E-cadherin
expression back to MDCK levels (Figure 8C). Accordingly,
vimentin expression was confirmed to reflect the morphol-
ogy of the cells.
Finally, we studied the relative motility of MDCK and
MDCK-RhoAQL cells and the effect Stat5a could have
over such motility. To this end, we performed a wound-
healing assay comparing the motility of the MDCK,
MDCK-Stat5aDN, MDCK-Stat5awt, MDCK-RhoAQL,
RhoAQL-Stat5aDN, and RhoAQL-Stat5awt stable cell
lines. Figure 8D shows representative pictures taken at 1
and 10 h after the wound was inflicted. MDCK and the
Stat5a transfectant cell lines had no visible motility. Con-
versely, RhoAQL-expressing cells were highly motile
compared with the parental MDCK cell line. Moreover,
whereas Stat5awt enhanced, Stat5aDN completely elimi-
nated the motility of MDCK-RhoAQL cells (Figure 8D).
The difference in relative motility between RhoAQL and
RhoAQL-Stat5awt cells was visible as early as 6 h (Figure
8D). Thus, Stat5a is necessary for the EMT induced by
RhoA.
Figure 8 (cont). Stat5a is necessary for RhoA-induced EMT, vimentin expression, and loss of E-cadherin and motility in MDCK cells. (A)
Stable expression of Stat5aDN or Stat5wt inhibits and enhances expression of vimentin induced by oncogenic RhoA, respectively. Stat5 stable
cells lines were generated as described in MATERIALS AND METHODS and were verified for Stat5DN (left) and Stat5awt (right) stable
expression with anti-Stat5a antibody and expression of endogenous vimentin with anti-vimentin. (B) Pictures of MDCK, MDCK-RhoAQL,
RhoAQL/Stat5DN, and RhoAQL/Stat5awt stable cell lines with representative morphological changes. (C) Stat5a is necessary for loss of
E-cadherin and vimentin expression accompanying RhoA-induced EM transition. Equal loading was verified with anti-tubulin. (D) Stat5a
modulates cell motility induced by oncogenic RhoA. Cell motility was monitored at 1-h intervals after scratching, and representative pictures
at 1 and 10 h are shown for each clone. An intermediate time point (6 h) is shown for RhoAQL- and RhoAQL/Stat5awt-expressing clones
(c, MDCK-control vector; dn, MDCK-Stat5aDN; wt, MDCK-Stat5awt; R, MDCK-RhoAQL; Rwt, MDCK-RhoAQL/Stat5awt; Rdn, MDCK-
RhoAQL/Stat5dn).
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DISCUSSION
We describe a novel signaling pathway that links RhoA to
the transcription factor Stat5a. Specifically, RhoA stimulated
activation of Stat5a, as demonstrated by inducible tyrosine
phosphorylation of both endogenous and ectopically ex-
pressed protein, DNA binding, and Sp1GLE Stat5-depen-
dent transcriptional activation. RhoA acts downstream of
LPA to orchestrate the signaling proteins required for
proper tyrosine phosphorylation of Stat5a that ultimately
leads to its transcriptional activation. The mechanism of
RhoA-induced tyrosine phosphorylation of Stat5a involved
JAK2 tyrosine kinase, because a dominant negative JAK2
mutant completely inhibited, and wild-type JAK2 greatly
enhanced, RhoA-mediated Stat5a tyrosine phosphorylation
and transcriptional activation. A functional interaction be-
tween JAK2 and Rho GTPases has been described previ-
ously (Simon et al., 2000; Aznar et al., 2001). In this sense,
both RhoA and Rac1 activate JAK2, which leads to tyrosine
phosphorylation of Stat3. Thus, JAK2 may represent a con-
vergence point between Rho signaling and Stat transcription
factors.
Interestingly, we have not observed tyrosine phosphory-
lation of Stat5b using a phosphospecific antibody that rec-
ognizes only its tyrosine phosphorylated form. We do not
know the functional implication of this finding, but several
works have already described a discrimination of Stat5a and
Stat5b activation after specific stimuli. In this sense, stimu-
lation of the promonocytic U937 cells with IFN- and IFN-
leads to tyrosine phosphorylation and transactivation of
Stat5a but not Stat5b (Meinke et al., 1996). The same study
reported that IFN- did not activate either Stat5a or Stat5b in
HeLa cells despite the expression of both Stat5 isoforms at
similar levels (Meinke et al., 1996). Furthermore, granulo-
cyte-monocyte colony–stimulating factor stimulates Stat5a
but not Stat5b activation in human peripheral-blood mono-
cytes (Rosen et al., 1996), whereas the same stimulus in
human neutrophils activates Stat5b and not Stat5a (Al-
Shami et al., 1998). Finally, selective gene disruption of
Stat5a or Stat5b in mice has dissected individual functions,
further pointing to the relevance of specific effects of each
Stat5 isoform (Levy and Gilliland, 2000).
We have found that oncogenic RhoA lowers the serine
phosphorylation content of Stat5a. Both Ser726 and Ser780
are constitutively phosphorylated under normal serum con-
ditions, and on RhoA expression, a strong dephosphoryla-
tion of serine 726 and a milder dephosphorylation of serine
780 take place that lead to an enhancement of Stat5a tran-
scriptional activity. The component that involves Stat5a
serine dephosphorylation is intriguing. Thus, RhoA directly
modulates the activity of yet to be identified Stat5a serine
kinases that phosphorylate Ser726 and Ser780. This down-
modulation might take place via direct inactivation of spe-
cific kinases responsible for Stat5a serine phosphorylation,
modulation of either their half-life or expression, or activa-
tion of a specific phosphatase. In contrast to what would be
expected from studies of Stat3 or Stat1, serine phosphoryla-
tion of Stat5a was found to be inhibitory in the cellular and
molecular context of the present work. Two recent studies
point to modulatory roles of Stat5a/b serine phosphoryla-
tion that may be positive or negative with regard to tran-
scriptional regulation (Park et al., 2001; Yamashita et al.,
2001). Thus, prolactin stimulation of murine mammary cells
leads to both tyrosine and serine phosphorylation of
Stat5a/b. However, Stat5 transcriptional activity in this con-
text remains latent. Subsequent glucocorticoid stimulation
does not affect Stat5 tyrosine phosphorylation but leads to
the serine dephosphorylation of both Stat5 isoforms, which
translates into an increase in Stat5 transcriptional activity
(Groner et al., 2000). Conversely, Stat5a-dependent transcrip-
tion of a GH-responsive ntcp-reporter gene positively de-
pends on Ser731 of Stat5b and Ser780 of Stat5a (and not
Ser726) (Park et al., 2001). Thus, mutation of these serine
residues to alanine in the context of GH leads to a decrease
in Stat5a/b transactivation. In contrast, mutants Stat5a-
S726/780A and Stat5b-S731A in the same cell system display
a twofold higher GH- or PRL-stimulated transcriptional ac-
tivity compared with their wild-type Stat5a/b when assayed
with a -casein promoter reporter (Park et al., 2001). This
clearly indicates that the promoter context used for measur-
ing Stat5a/b transcriptional activity with respect to its serine
phosphorylation is a key element to take into account. In the
present study, we provide further evidence for a suppres-
sive effect of serine phosphorylation on Stat5a transcription
in the context of the Sp2.1 promoter and RhoA signaling.
Attempts have been made to identify the mechanism for
regulation of serine dephosphorylation. Our results demon-
strate that treatment with the specific inhibitor PD98059
enhances the transcriptional activity of Stat5a. This effect is
associated with dephosphorylation of S726 but not Ser780;
PD98059 treatment related directly only to Ser726 dephos-
phorylation, because the S726A mutant was unaffected by
PD98059, whereas the S780A mutant showed an increase in
activity when treated with PD98059. However, RhoA does
not modulate MEK1 activity in this cell line, indicating that
both MEK1 and RhoA affect Stat5a serine phosphorylation
by two independent mechanisms. These results are also
consistent with a second, unidentified, serine kinase in-
volved in the regulation of the S780 residue.
We have also established that a p38-dependent signal
affects Stat5a regulation. Inhibition of p38 by SB203580 re-
sulted in an increase in Stat5a activity. However, contrary to
MEK1 blockage, inhibition of p38 had no effect on the phos-
phorylation state of either Ser726 or Ser780. These results are
intriguing, because both serines are insensitive to p38 inhi-
bition, and it would be expected that both Stat5a serine
mutants show the same increase in transcriptional activity as
the wild-type Stat5a does. Given that the activity of both
mutants is the same in SB203580-treated and untreated cells,
this implies an indirect mechanism; for instance, a protein
interaction that depends on two intact serine residues of
Stat5a, whereby mutation of either serine residue would
eliminate this interaction and its inhibitory activity, thus
eliminating the sensitivity to SB203580. Alternatively, p38
might modulate Stat5a activity via a novel serine residue.
Furthermore, as for MEK1, no functional interaction be-
tween RhoA and p38 was found, indicating that both pro-
teins modulate Stat5a activity by two independent mecha-
nisms. To the best of our knowledge, this is the first evidence
of a modulatory role for p38 on Stat5a. With respect to JNK,
we have not found any modulatory action of this pathway
over serine phosphorylation or transcriptional activity of
Stat5a in the context of RhoA.
Although the present study demonstrated that RhoA ac-
tivated Stat5a, the two other prototypes of Rho GTPases,
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Rac1 and Cdc42, were also capable of inducing Sp1GLE
Stat5–dependent transcriptional activation in specific cell
lines such as MCF-7 or CHO-4. However, the pattern of
Sp1GLE transcription downstream of Rho GTPases differed
depending on the cell line used. Thus, whereas Rho is
capable of efficiently triggering Sp1GLE transcription in
MDCK cells, Rac1 and Cdc42 fail to induce either tyrosine
phosphorylation or transcriptional activation of Stat5a.
Furthermore, we have found that oncogenic RhoC (V12) is
also capable of triggering transcriptional activation of
Stat5 in MCF7 and HeLa cells. Given that RhoC was
recently found to be overexpressed in 90% of inflamma-
tory metastatic breast cancer and that expression of RhoC
in human mammary epithelium mimics the inflammatory
metastatic breast cancer phenotype, the role of Stat5a in
RhoC-induced neoplastic transformation is of direct inter-
est. Furthermore, the specific mechanism whereby Rac1,
Cdc42, or RhoC activates Stat5a or Stat5b remains to be
determined.
Finally, we have determined that Stat5a is necessary for
RhoA-induced EMT. Several works have pointed out a role
of Rho GTPases in cell shape and motility (Evers et al., 2000;
Ridley, 2001). For instance, RhoA is necessary for some of
the morphological changes necessary for the EM transition
of Ras-transformed mammary epithelial cells (Zhong et al.,
1997). Also, RhoA mediates both transforming growth fac-
tor-– (1 and 3) and Ras-induced transition to a fibroblastic
phenotype of epithelial cells (Bakin et al., 2000; Zondag et al.,
2000; Bhowmick et al., 2001; Kaartinen et al., 2002). In our
system, modulation of Stat5a activity modulates the neces-
sary elements essential for this cytoskeletal change induced
by RhoA. This same effect was recently described for SRF,
whose activity is modulated by changes in actin dynamics
necessary for the epithelial to mesenchymal transition of
tumor cells induced by RhoA (Sotiropoulos et al., 1999;
Psichari et al., 2002). SRF-induced EMT takes place via ex-
pression of vinculin, actin, and SRF itself. In our particular
system, we have observed that Stat5a modulates the expres-
sion of vimentin and E-cadherin. Whether SRF and Stat5a
cooperate functionally to promote EMT is currently un-
known. To the best of our knowledge, this is the first evi-
dence of a role for Stat5 in the cytoskeletal changes that
occur during EMT. Although Stat3 has been implicated in
hepatocyte growth factor–induced tubulogenesis, we do not
know whether both family members cooperate in this pro-
cess (Boccaccio et al., 1998). With this in mind, we do not
exclude the possibility that Stat5a might be involved in EM
transition in a more general manner rather than only down-
stream of RhoA. Rho is capable of regulating cell adhesion
both in a positive and in a negative manner depending on
the stimulus and the intracellular pathways activated,
namely ROCK and mDia, respectively (Sahai and Marshall,
2002). In our context, whether Stat5a is only positively im-
plicated in RhoA-induced EMT via ROCK, or by contrast
whether it constitutes a modulatory mechanism exerted by
Rho on specific extracellular stimuli and matrix components
to either disrupt or stabilize adherens junctions, is currently
under study.
Thus, both these findings further potentiate the knowl-
edge that regulation of transcription exerts profound effects
in Rho GTPase–meditated functions that ultimately lead, in
the context of tumoral cells, to a transformed phenotype.
Together, these results point to a general role of Stat proteins
in the biological functions of Rho GTPases.
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